Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WIZ | O95785 | 3/20 | 0.55 |
| ▸ | CRBN | Q96SW2 | 12/20 | 0.55 |
| ▸ | IKZF2 | Q9UKS7 | 6/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24319331 | 0.89 | CRBN (0.69) | WIZCRBNIKZF2CSNK1A1 | |
| SCHEMBL17552859 | 0.89 | CRBN (0.69) | WIZCRBNIKZF2CSNK1A1 | |
| SCHEMBL24833121 | 0.84 | CRBN (0.58) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL21464529 | 0.83 | WIZ (0.51) | WIZCRBNIKZF2 | |
| SCHEMBL19503629 | 0.82 | CRBN (0.72) | WIZCRBNIKZF2CSNK1A1 | |
| SCHEMBL21464551 | 0.82 | CRBN (0.80) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL23594559 | 0.81 | IKZF1 (0.55) | WIZCRBNIKZF2CSNK1A1 | |
| SCHEMBL31158936 | 0.79 | CRBN (0.53) | WIZCRBNIKZF2CSNK1A1 | |
| SCHEMBL26930468 | 0.79 | HTR2C (0.51) | WIZCRBNIKZF2CSNK1A1HTR2C | |
| SCHEMBL17174015 | 0.79 | CRBN (0.78) | CRBNCSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360219-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12239711-B2 | Cereblon ligands and bifunctional compounds comprising the same | ARVINAS OPERATIONS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| CN-118480030-A | Cerebulin ligands and bifunctional compounds comprising same | 阿尔维纳斯运营股份有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-112262134-B | Cerebulin ligands and bifunctional compounds comprising same | 阿尔维纳斯运营股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20230082997-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2023-03-16 | — | — | US | disclosed |
| EP-3774772-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | Arvinas Operations, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-112262134-A | Cereblon ligand and bifunctional compound comprising same | 阿尔维纳斯运营股份有限公司 | 2021-01-22 | — | — | CN | disclosed |
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200155690-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200155690-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2020-05-21 | — | — | US | disclosed |
| WO-2019199816-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019199816-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360219-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | WIZ 1589/4885CRBN 1/4885IKZF2 1770/4885 |
| US-12239711-B2 | Cereblon ligands and bifunctional compounds comprising the same | CRBN, CBL, MDM2 | WIZ 1589/4885CRBN 1/4885IKZF2 1770/4885 |
| US-20230082997-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | WIZ 1589/4885CRBN 1/4885IKZF2 1770/4885 |
| US-20200155690-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | WIZ 1589/4885CRBN 1/4885IKZF2 1770/4885 |
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | WIZ 1589/4885CRBN 1/4885IKZF2 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.